GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » ROA %

CARsgen Therapeutics Holdings (HKSE:02171) ROA % : -28.01% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CARsgen Therapeutics Holdings's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-751.04 Mil. CARsgen Therapeutics Holdings's average Total Assets over the quarter that ended in Dec. 2023 was HK$2,680.95 Mil. Therefore, CARsgen Therapeutics Holdings's annualized ROA % for the quarter that ended in Dec. 2023 was -28.01%.

The historical rank and industry rank for CARsgen Therapeutics Holdings's ROA % or its related term are showing as below:

HKSE:02171' s ROA % Range Over the Past 10 Years
Min: -201.06   Med: -81.38   Max: -27.01
Current: -29.05

During the past 5 years, CARsgen Therapeutics Holdings's highest ROA % was -27.01%. The lowest was -201.06%. And the median was -81.38%.

HKSE:02171's ROA % is ranked better than
55.2% of 1549 companies
in the Biotechnology industry
Industry Median: -34.69 vs HKSE:02171: -29.05

CARsgen Therapeutics Holdings ROA % Historical Data

The historical data trend for CARsgen Therapeutics Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings ROA % Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-81.38 -136.44 -201.06 -27.01 -29.45

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only -19.32 -21.69 -33.25 -29.60 -28.01

Competitive Comparison of CARsgen Therapeutics Holdings's ROA %

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's ROA % falls into.



CARsgen Therapeutics Holdings ROA % Calculation

CARsgen Therapeutics Holdings's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-817.921/( (3085.281+2468.893)/ 2 )
=-817.921/2777.087
=-29.45 %

CARsgen Therapeutics Holdings's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-751.036/( (2893.003+2468.893)/ 2 )
=-751.036/2680.948
=-28.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


CARsgen Therapeutics Holdings  (HKSE:02171) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-751.036/2680.948
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-751.036 / 0)*(0 / 2680.948)
=Net Margin %*Asset Turnover
=N/A %*0
=-28.01 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


CARsgen Therapeutics Holdings ROA % Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Traded in Other Exchanges
Address
No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines